APO Research
Talk to an analyst

APO RESEARCH · REPORT

Computer-assisted Drug Design Platform

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Computer-assisted Drug Design Platform Market Outlook and Growth Opportunities 2026

2 May 2026197 pages

Choose your research edition.

Industry ResearchComputer-assisted Drug Design Platform Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal Computer-assisted Drug Design Platform Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Computer-assisted Drug Design Platform Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Computer-assisted Drug Design Platform Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Computer-assisted Drug Design Platform Market Analysis and Forecast 2026-2032206 pages · $4,950 USD

Market perspective

The global Computer-assisted Drug Design Platform market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Computer-assisted Drug Design Platform is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Computer-assisted Drug Design Platform is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Computer-assisted Drug Design Platform is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Computer-assisted Drug Design Platform market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Computer-assisted Drug Design Platform market include Entelos, Crown Bioscience, Chemical Computing Group, Nimbus Therapeutics, Schrodinger, Dassault Systemes, Genedata, Biognos and Leadscope, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Computer-assisted Drug Design Platform market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Computer-assisted Drug Design Platform and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Computer-assisted Drug Design Platform revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Computer-assisted Drug Design Platform market.

Computer-assisted Drug Design Platform Segment by Company

Entelos

Crown Bioscience

Chemical Computing Group

Nimbus Therapeutics

Schrodinger

Dassault Systemes

Genedata

Biognos

Leadscope

Rhenovia Pharma Limited

Compugen

Certara LP

Prosarix

Simulations Plus

Strand Life Sciences

Computer-assisted Drug Design Platform Segment by Type

Cloud-based

On-premise

Computer-assisted Drug Design Platform Segment by Application

Drug Discovery and Development

Computational Physiological Medicine

Disease Modeling

Medical Imaging

Predictive Analysis of Drug Targets

Computer-assisted Drug Design Platform Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Computer-assisted Drug Design Platform status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Computer-assisted Drug Design Platform key companies, revenue, market share, and recent developments.

3. To split the Computer-assisted Drug Design Platform breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Computer-assisted Drug Design Platform market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Computer-assisted Drug Design Platform significant trends, drivers, influence factors in global and regions.

6. To analyze Computer-assisted Drug Design Platform competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Computer-assisted Drug Design Platform market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Computer-assisted Drug Design Platform and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Computer-assisted Drug Design Platform.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Computer-assisted Drug Design Platform industry.

Chapter 3: Detailed analysis of Computer-assisted Drug Design Platform company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Computer-assisted Drug Design Platform in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Computer-assisted Drug Design Platform in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Computer-assisted Drug Design Platform Industry Trends Table 2. Computer-assisted Drug Design Platform Industry Drivers Table 3. Computer-assisted Drug Design Platform Industry Opportunities and Challenges Table 4. Computer-assisted Drug Design Platform Industry Restraints Table 5. Global Computer-assisted Drug Design Platform Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Computer-assisted Drug Design Platform Revenue Share by Company (2021-2026) Table 7. Global Computer-assisted Drug Design Platform Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Computer-assisted Drug Design Platform Key Company Manufacturing Base & Headquarters Table 9. Global Computer-assisted Drug Design Platform Company, Product Type & Application Table 10. Global Computer-assisted Drug Design Platform Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Computer-assisted Drug Design Platform by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Cloud-based Table 15. Significant Companies of On-premise Table 16. Global Computer-assisted Drug Design Platform Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Computer-assisted Drug Design Platform Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Computer-assisted Drug Design Platform Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Computer-assisted Drug Design Platform Sales Value Share by Type (2021-2026) Table 20. Global Computer-assisted Drug Design Platform Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Drug Discovery and Development Table 22. Significant Companies of Computational Physiological Medicine Table 23. Significant Companies of Disease Modeling Table 24. Significant Companies of Medical Imaging Table 25. Significant Companies of Predictive Analysis of Drug Targets Table 26. Global Computer-assisted Drug Design Platform Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Computer-assisted Drug Design Platform Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Computer-assisted Drug Design Platform Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Computer-assisted Drug Design Platform Sales Value Share by Application (2021-2026) Table 30. Global Computer-assisted Drug Design Platform Sales Value Share by Application (2027-2032) Table 31. Global Computer-assisted Drug Design Platform Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Computer-assisted Drug Design Platform Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Computer-assisted Drug Design Platform Sales Value Share by Region (2021-2026) Table 34. Global Computer-assisted Drug Design Platform Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Computer-assisted Drug Design Platform Sales Value Share by Region (2027-2032) Table 36. Global Computer-assisted Drug Design Platform Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Computer-assisted Drug Design Platform Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Computer-assisted Drug Design Platform Sales Value Market Share by Country (2021-2026) Table 39. Global Computer-assisted Drug Design Platform Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Computer-assisted Drug Design Platform Sales Value Market Share by Country (2027-2032) Table 41. Entelos Company Information Table 42. Entelos Business Overview Table 43. Entelos Computer-assisted Drug Design Platform Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Entelos Computer-assisted Drug Design Platform Product Portfolio Table 45. Entelos Recent Development Table 46. Crown Bioscience Company Information Table 47. Crown Bioscience Business Overview Table 48. Crown Bioscience Computer-assisted Drug Design Platform Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Crown Bioscience Computer-assisted Drug Design Platform Product Portfolio Table 50. Crown Bioscience Recent Development Table 51. Chemical Computing Group Company Information Table 52. Chemical Computing Group Business Overview Table 53. Chemical Computing Group Computer-assisted Drug Design Platform Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Chemical Computing Group Computer-assisted Drug Design Platform Product Portfolio Table 55. Chemical Computing Group Recent Development Table 56. Nimbus Therapeutics Company Information Table 57. Nimbus Therapeutics Business Overview Table 58. Nimbus Therapeutics Computer-assisted Drug Design Platform Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Nimbus Therapeutics Computer-assisted Drug Design Platform Product Portfolio Table 60. Nimbus Therapeutics Recent Development Table 61. Schrodinger Company Information Table 62. Schrodinger Business Overview Table 63. Schrodinger Computer-assisted Drug Design Platform Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Schrodinger Computer-assisted Drug Design Platform Product Portfolio Table 65. Schrodinger Recent Development Table 66. Dassault Systemes Company Information Table 67. Dassault Systemes Business Overview Table 68. Dassault Systemes Computer-assisted Drug Design Platform Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Dassault Systemes Computer-assisted Drug Design Platform Product Portfolio Table 70. Dassault Systemes Recent Development Table 71. Genedata Company Information Table 72. Genedata Business Overview Table 73. Genedata Computer-assisted Drug Design Platform Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Genedata Computer-assisted Drug Design Platform Product Portfolio Table 75. Genedata Recent Development Table 76. Biognos Company Information Table 77. Biognos Business Overview Table 78. Biognos Computer-assisted Drug Design Platform Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Biognos Computer-assisted Drug Design Platform Product Portfolio Table 80. Biognos Recent Development Table 81. Leadscope Company Information Table 82. Leadscope Business Overview Table 83. Leadscope Computer-assisted Drug Design Platform Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Leadscope Computer-assisted Drug Design Platform Product Portfolio Table 85. Leadscope Recent Development Table 86. Rhenovia Pharma Limited Company Information Table 87. Rhenovia Pharma Limited Business Overview Table 88. Rhenovia Pharma Limited Computer-assisted Drug Design Platform Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Rhenovia Pharma Limited Computer-assisted Drug Design Platform Product Portfolio Table 90. Rhenovia Pharma Limited Recent Development Table 91. Compugen Company Information Table 92. Compugen Business Overview Table 93. Compugen Computer-assisted Drug Design Platform Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 94. Compugen Computer-assisted Drug Design Platform Product Portfolio Table 95. Compugen Recent Development Table 96. Certara LP Company Information Table 97. Certara LP Business Overview Table 98. Certara LP Computer-assisted Drug Design Platform Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 99. Certara LP Computer-assisted Drug Design Platform Product Portfolio Table 100. Certara LP Recent Development Table 101. Prosarix Company Information Table 102. Prosarix Business Overview Table 103. Prosarix Computer-assisted Drug Design Platform Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 104. Prosarix Computer-assisted Drug Design Platform Product Portfolio Table 105. Prosarix Recent Development Table 106. Simulations Plus Company Information Table 107. Simulations Plus Business Overview Table 108. Simulations Plus Computer-assisted Drug Design Platform Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 109. Simulations Plus Computer-assisted Drug Design Platform Product Portfolio Table 110. Simulations Plus Recent Development Table 111. Strand Life Sciences Company Information Table 112. Strand Life Sciences Business Overview Table 113. Strand Life Sciences Computer-assisted Drug Design Platform Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 114. Strand Life Sciences Computer-assisted Drug Design Platform Product Portfolio Table 115. Strand Life Sciences Recent Development Table 116. Research Programs/Design for This Report Table 117. Authors List of This Report Table 118. Secondary Sources Table 119. Primary Sources List of Figures Figure 1. Computer-assisted Drug Design Platform Product Image Figure 2. Global Computer-assisted Drug Design Platform Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Computer-assisted Drug Design Platform Market Size (2021-2032) & (US$ Million) Figure 4. Global Computer-assisted Drug Design Platform Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Cloud-based Image Figure 8. On-premise Image Figure 9. Global Computer-assisted Drug Design Platform Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Computer-assisted Drug Design Platform Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Computer-assisted Drug Design Platform Sales Value Share by Type (2021-2032) Figure 12. Drug Discovery and Development Image Figure 13. Computational Physiological Medicine Image Figure 14. Disease Modeling Image Figure 15. Medical Imaging Image Figure 16. Predictive Analysis of Drug Targets Image Figure 17. Global Computer-assisted Drug Design Platform Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Computer-assisted Drug Design Platform Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Computer-assisted Drug Design Platform Sales Value Share by Application (2021-2032) Figure 20. Global Computer-assisted Drug Design Platform Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Computer-assisted Drug Design Platform Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Computer-assisted Drug Design Platform Sales Value (2021-2032) & (US$ Million) Figure 23. North America Computer-assisted Drug Design Platform Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Computer-assisted Drug Design Platform Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Computer-assisted Drug Design Platform Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Computer-assisted Drug Design Platform Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Computer-assisted Drug Design Platform Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Computer-assisted Drug Design Platform Sales Value (2021-2032) & (US$ Million) Figure 29. South America Computer-assisted Drug Design Platform Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Computer-assisted Drug Design Platform Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Computer-assisted Drug Design Platform Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Computer-assisted Drug Design Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Computer-assisted Drug Design Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Computer-assisted Drug Design Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Computer-assisted Drug Design Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Computer-assisted Drug Design Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Computer-assisted Drug Design Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Computer-assisted Drug Design Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Computer-assisted Drug Design Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Computer-assisted Drug Design Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Computer-assisted Drug Design Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Computer-assisted Drug Design Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Computer-assisted Drug Design Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Computer-assisted Drug Design Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Computer-assisted Drug Design Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Computer-assisted Drug Design Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Computer-assisted Drug Design Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Computer-assisted Drug Design Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Computer-assisted Drug Design Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Computer-assisted Drug Design Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Computer-assisted Drug Design Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Computer-assisted Drug Design Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Computer-assisted Drug Design Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Computer-assisted Drug Design Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Computer-assisted Drug Design Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Computer-assisted Drug Design Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Computer-assisted Drug Design Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Computer-assisted Drug Design Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Computer-assisted Drug Design Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Computer-assisted Drug Design Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Computer-assisted Drug Design Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Computer-assisted Drug Design Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Computer-assisted Drug Design Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Computer-assisted Drug Design Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Computer-assisted Drug Design Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Computer-assisted Drug Design Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Computer-assisted Drug Design Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Computer-assisted Drug Design Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Computer-assisted Drug Design Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Computer-assisted Drug Design Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Computer-assisted Drug Design Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Computer-assisted Drug Design Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Computer-assisted Drug Design Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Computer-assisted Drug Design Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Computer-assisted Drug Design Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Computer-assisted Drug Design Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Computer-assisted Drug Design Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Computer-assisted Drug Design Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Computer-assisted Drug Design Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Computer-assisted Drug Design Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Computer-assisted Drug Design Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Computer-assisted Drug Design Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Computer-assisted Drug Design Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Computer-assisted Drug Design Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Computer-assisted Drug Design Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Computer-assisted Drug Design Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Computer-assisted Drug Design Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Computer-assisted Drug Design Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Computer-assisted Drug Design Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Computer-assisted Drug Design Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Computer-assisted Drug Design Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Computer-assisted Drug Design Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Computer-assisted Drug Design Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Computer-assisted Drug Design Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Computer-assisted Drug Design Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Computer-assisted Drug Design Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Computer-assisted Drug Design Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Computer-assisted Drug Design Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Computer-assisted Drug Design Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Computer-assisted Drug Design Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Computer-assisted Drug Design Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Computer-assisted Drug Design Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Computer-assisted Drug Design Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Computer-assisted Drug Design Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Computer-assisted Drug Design Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Computer-assisted Drug Design Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Computer-assisted Drug Design Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Computer-assisted Drug Design Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Computer-assisted Drug Design Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Computer-assisted Drug Design Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Computer-assisted Drug Design Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Computer-assisted Drug Design Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Computer-assisted Drug Design Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Computer-assisted Drug Design Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Computer-assisted Drug Design Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Cloud-based
  • On-premise
Applications
  • Drug Discovery and Development
  • Computational Physiological Medicine
  • Disease Modeling
  • Medical Imaging
  • Predictive Analysis of Drug Targets
Companies covered
  • Entelos
  • Crown Bioscience
  • Chemical Computing Group
  • Nimbus Therapeutics
  • Schrodinger
  • Dassault Systemes
  • Genedata
  • Biognos
  • Leadscope
  • Rhenovia Pharma Limited
  • Compugen
  • Certara LP
  • Prosarix
  • Simulations Plus
  • Strand Life Sciences

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Computer-assisted Drug Design Platform Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Computer-assisted Drug Design Platform Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Computer-assisted Drug Design Platform Market Dynamics
  1. 2.1 Computer-assisted Drug Design Platform Industry Trends
  2. 2.2 Computer-assisted Drug Design Platform Industry Drivers
  3. 2.3 Computer-assisted Drug Design Platform Industry Opportunities and Challenges
  4. 2.4 Computer-assisted Drug Design Platform Industry Restraints
3 Computer-assisted Drug Design Platform Market by Company
  1. 3.1 Global Computer-assisted Drug Design Platform Company Revenue Ranking in 2025
  2. 3.2 Global Computer-assisted Drug Design Platform Revenue by Company (2021-2026)
  3. 3.3 Global Computer-assisted Drug Design Platform Company Ranking (2024-2026)
  4. 3.4 Global Computer-assisted Drug Design Platform Company Manufacturing Base and Headquarters
  5. 3.5 Global Computer-assisted Drug Design Platform Company Product Type and Application
  6. 3.6 Global Computer-assisted Drug Design Platform Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Computer-assisted Drug Design Platform Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Computer-assisted Drug Design Platform Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Computer-assisted Drug Design Platform Market by Type
  1. 4.1 Computer-assisted Drug Design Platform Type Introduction
  2. 4.1.1 Cloud-based
  3. 4.1.2 On-premise
  4. 4.2 Global Computer-assisted Drug Design Platform Sales Value by Type
  5. 4.2.1 Global Computer-assisted Drug Design Platform Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Computer-assisted Drug Design Platform Sales Value by Type (2021-2032)
  7. 4.2.3 Global Computer-assisted Drug Design Platform Sales Value Share by Type (2021-2032)
5 Computer-assisted Drug Design Platform Market by Application
  1. 5.1 Computer-assisted Drug Design Platform Application Introduction
  2. 5.1.1 Drug Discovery and Development
  3. 5.1.2 Computational Physiological Medicine
  4. 5.1.3 Disease Modeling
  5. 5.1.4 Medical Imaging
  6. 5.1.5 Predictive Analysis of Drug Targets
  7. 5.2 Global Computer-assisted Drug Design Platform Sales Value by Application
  8. 5.2.1 Global Computer-assisted Drug Design Platform Sales Value by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Computer-assisted Drug Design Platform Sales Value by Application (2021-2032)
  10. 5.2.3 Global Computer-assisted Drug Design Platform Sales Value Share by Application (2021-2032)
6 Computer-assisted Drug Design Platform Regional Value Analysis
  1. 6.1 Global Computer-assisted Drug Design Platform Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Computer-assisted Drug Design Platform Sales Value by Region (2021-2032)
  3. 6.2.1 Global Computer-assisted Drug Design Platform Sales Value by Region: 2021-2026
  4. 6.2.2 Global Computer-assisted Drug Design Platform Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Computer-assisted Drug Design Platform Sales Value (2021-2032)
  7. 6.3.2 North America Computer-assisted Drug Design Platform Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Computer-assisted Drug Design Platform Sales Value (2021-2032)
  10. 6.4.2 Europe Computer-assisted Drug Design Platform Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Computer-assisted Drug Design Platform Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Computer-assisted Drug Design Platform Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Computer-assisted Drug Design Platform Sales Value (2021-2032)
  16. 6.6.2 South America Computer-assisted Drug Design Platform Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Computer-assisted Drug Design Platform Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Computer-assisted Drug Design Platform Sales Value Share by Country, 2025 VS 2032
7 Computer-assisted Drug Design Platform Country-level Value Analysis
  1. 7.1 Global Computer-assisted Drug Design Platform Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Computer-assisted Drug Design Platform Sales Value by Country (2021-2032)
  3. 7.2.1 Global Computer-assisted Drug Design Platform Sales Value by Country (2021-2026)
  4. 7.2.2 Global Computer-assisted Drug Design Platform Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Computer-assisted Drug Design Platform Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Computer-assisted Drug Design Platform Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Computer-assisted Drug Design Platform Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Computer-assisted Drug Design Platform Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Computer-assisted Drug Design Platform Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Computer-assisted Drug Design Platform Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Computer-assisted Drug Design Platform Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Computer-assisted Drug Design Platform Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Computer-assisted Drug Design Platform Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Computer-assisted Drug Design Platform Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Computer-assisted Drug Design Platform Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Computer-assisted Drug Design Platform Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Computer-assisted Drug Design Platform Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Computer-assisted Drug Design Platform Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Computer-assisted Drug Design Platform Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Computer-assisted Drug Design Platform Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Computer-assisted Drug Design Platform Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Computer-assisted Drug Design Platform Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Computer-assisted Drug Design Platform Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Computer-assisted Drug Design Platform Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Computer-assisted Drug Design Platform Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Computer-assisted Drug Design Platform Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Computer-assisted Drug Design Platform Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Computer-assisted Drug Design Platform Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Computer-assisted Drug Design Platform Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Computer-assisted Drug Design Platform Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Computer-assisted Drug Design Platform Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Computer-assisted Drug Design Platform Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Computer-assisted Drug Design Platform Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Computer-assisted Drug Design Platform Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Computer-assisted Drug Design Platform Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Computer-assisted Drug Design Platform Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Computer-assisted Drug Design Platform Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Computer-assisted Drug Design Platform Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Computer-assisted Drug Design Platform Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Computer-assisted Drug Design Platform Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Computer-assisted Drug Design Platform Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Computer-assisted Drug Design Platform Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Computer-assisted Drug Design Platform Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Computer-assisted Drug Design Platform Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Computer-assisted Drug Design Platform Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Computer-assisted Drug Design Platform Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Computer-assisted Drug Design Platform Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Computer-assisted Drug Design Platform Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Computer-assisted Drug Design Platform Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Computer-assisted Drug Design Platform Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Computer-assisted Drug Design Platform Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Computer-assisted Drug Design Platform Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Computer-assisted Drug Design Platform Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Computer-assisted Drug Design Platform Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Computer-assisted Drug Design Platform Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Computer-assisted Drug Design Platform Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Computer-assisted Drug Design Platform Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Computer-assisted Drug Design Platform Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Computer-assisted Drug Design Platform Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Computer-assisted Drug Design Platform Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Computer-assisted Drug Design Platform Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Computer-assisted Drug Design Platform Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Computer-assisted Drug Design Platform Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Computer-assisted Drug Design Platform Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Computer-assisted Drug Design Platform Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Computer-assisted Drug Design Platform Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Computer-assisted Drug Design Platform Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Computer-assisted Drug Design Platform Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Computer-assisted Drug Design Platform Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Computer-assisted Drug Design Platform Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Computer-assisted Drug Design Platform Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Computer-assisted Drug Design Platform Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Computer-assisted Drug Design Platform Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Computer-assisted Drug Design Platform Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Computer-assisted Drug Design Platform Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Computer-assisted Drug Design Platform Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Computer-assisted Drug Design Platform Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Computer-assisted Drug Design Platform Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Computer-assisted Drug Design Platform Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Computer-assisted Drug Design Platform Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Computer-assisted Drug Design Platform Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Computer-assisted Drug Design Platform Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Computer-assisted Drug Design Platform Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Computer-assisted Drug Design Platform Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Computer-assisted Drug Design Platform Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Computer-assisted Drug Design Platform Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Computer-assisted Drug Design Platform Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Computer-assisted Drug Design Platform Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Entelos
  2. 8.1.1 Entelos Company Information
  3. 8.1.2 Entelos Business Overview
  4. 8.1.3 Entelos Computer-assisted Drug Design Platform Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Entelos Computer-assisted Drug Design Platform Product Portfolio
  6. 8.1.5 Entelos Recent Developments
  7. 8.2 Crown Bioscience
  8. 8.2.1 Crown Bioscience Company Information
  9. 8.2.2 Crown Bioscience Business Overview
  10. 8.2.3 Crown Bioscience Computer-assisted Drug Design Platform Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Crown Bioscience Computer-assisted Drug Design Platform Product Portfolio
  12. 8.2.5 Crown Bioscience Recent Developments
  13. 8.3 Chemical Computing Group
  14. 8.3.1 Chemical Computing Group Company Information
  15. 8.3.2 Chemical Computing Group Business Overview
  16. 8.3.3 Chemical Computing Group Computer-assisted Drug Design Platform Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Chemical Computing Group Computer-assisted Drug Design Platform Product Portfolio
  18. 8.3.5 Chemical Computing Group Recent Developments
  19. 8.4 Nimbus Therapeutics
  20. 8.4.1 Nimbus Therapeutics Company Information
  21. 8.4.2 Nimbus Therapeutics Business Overview
  22. 8.4.3 Nimbus Therapeutics Computer-assisted Drug Design Platform Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Nimbus Therapeutics Computer-assisted Drug Design Platform Product Portfolio
  24. 8.4.5 Nimbus Therapeutics Recent Developments
  25. 8.5 Schrodinger
  26. 8.5.1 Schrodinger Company Information
  27. 8.5.2 Schrodinger Business Overview
  28. 8.5.3 Schrodinger Computer-assisted Drug Design Platform Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Schrodinger Computer-assisted Drug Design Platform Product Portfolio
  30. 8.5.5 Schrodinger Recent Developments
  31. 8.6 Dassault Systemes
  32. 8.6.1 Dassault Systemes Company Information
  33. 8.6.2 Dassault Systemes Business Overview
  34. 8.6.3 Dassault Systemes Computer-assisted Drug Design Platform Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Dassault Systemes Computer-assisted Drug Design Platform Product Portfolio
  36. 8.6.5 Dassault Systemes Recent Developments
  37. 8.7 Genedata
  38. 8.7.1 Genedata Company Information
  39. 8.7.2 Genedata Business Overview
  40. 8.7.3 Genedata Computer-assisted Drug Design Platform Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Genedata Computer-assisted Drug Design Platform Product Portfolio
  42. 8.7.5 Genedata Recent Developments
  43. 8.8 Biognos
  44. 8.8.1 Biognos Company Information
  45. 8.8.2 Biognos Business Overview
  46. 8.8.3 Biognos Computer-assisted Drug Design Platform Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Biognos Computer-assisted Drug Design Platform Product Portfolio
  48. 8.8.5 Biognos Recent Developments
  49. 8.9 Leadscope
  50. 8.9.1 Leadscope Company Information
  51. 8.9.2 Leadscope Business Overview
  52. 8.9.3 Leadscope Computer-assisted Drug Design Platform Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Leadscope Computer-assisted Drug Design Platform Product Portfolio
  54. 8.9.5 Leadscope Recent Developments
  55. 8.10 Rhenovia Pharma Limited
  56. 8.10.1 Rhenovia Pharma Limited Company Information
  57. 8.10.2 Rhenovia Pharma Limited Business Overview
  58. 8.10.3 Rhenovia Pharma Limited Computer-assisted Drug Design Platform Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Rhenovia Pharma Limited Computer-assisted Drug Design Platform Product Portfolio
  60. 8.10.5 Rhenovia Pharma Limited Recent Developments
  61. 8.11 Compugen
  62. 8.11.1 Compugen Company Information
  63. 8.11.2 Compugen Business Overview
  64. 8.11.3 Compugen Computer-assisted Drug Design Platform Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Compugen Computer-assisted Drug Design Platform Product Portfolio
  66. 8.11.5 Compugen Recent Developments
  67. 8.12 Certara LP
  68. 8.12.1 Certara LP Company Information
  69. 8.12.2 Certara LP Business Overview
  70. 8.12.3 Certara LP Computer-assisted Drug Design Platform Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Certara LP Computer-assisted Drug Design Platform Product Portfolio
  72. 8.12.5 Certara LP Recent Developments
  73. 8.13 Prosarix
  74. 8.13.1 Prosarix Company Information
  75. 8.13.2 Prosarix Business Overview
  76. 8.13.3 Prosarix Computer-assisted Drug Design Platform Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Prosarix Computer-assisted Drug Design Platform Product Portfolio
  78. 8.13.5 Prosarix Recent Developments
  79. 8.14 Simulations Plus
  80. 8.14.1 Simulations Plus Company Information
  81. 8.14.2 Simulations Plus Business Overview
  82. 8.14.3 Simulations Plus Computer-assisted Drug Design Platform Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Simulations Plus Computer-assisted Drug Design Platform Product Portfolio
  84. 8.14.5 Simulations Plus Recent Developments
  85. 8.15 Strand Life Sciences
  86. 8.15.1 Strand Life Sciences Company Information
  87. 8.15.2 Strand Life Sciences Business Overview
  88. 8.15.3 Strand Life Sciences Computer-assisted Drug Design Platform Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Strand Life Sciences Computer-assisted Drug Design Platform Product Portfolio
  90. 8.15.5 Strand Life Sciences Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst